TABLE 2.
Results from VENUS Study Subgroup Analyses of Patients with Poor Outcome in Each Group
| Nimodipine | Placebo | RR | 95% CI | |
|---|---|---|---|---|
| Ischemic stroke | n = 133 | n = 128 | ||
| Poor outcome at 3 months | 44 (34) | 30 (24) | 1.4 | 1.0–2.1 |
| Hemorrhagic stroke | n = 20 | n = 15 | ||
| Poor outcome at 3 months | 11 (58) | 9 (60) | 1.0 | 0.6–1.7 |
| No CT scan | n = 71 | n = 79 | ||
| Poor outcome at 3 months | 16 (23) | 21 (27) | 0.8 | 0.5–1.5 |
| Per protocol* | n = 179 | n = 168 | ||
| Poor outcome at 3 months | 56 (31) | 47 (28) | 1.1 | 0.8–1.6 |
*
107 patients were excluded from this analysis because of the following exclusion criteria: 8, other diagnosis; 74, hemiparesis not severe enough; 8, age >85 years; 10, swallowing disturbance; and 7, other exclusion criteria.17
Values are number (%) unless indicated otherwise.
CI = confidence interval; RR = relative risk.
From Horn et al. Very early nimodipine use in stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 32:461. Copyright © 2001, Lippincott Williams and Wilkins. All rights reserved.